Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
London, United Kingdom
- Research Site
Oxford, United Kingdom
- Research Site
Los Angeles, California, United States
- Research Site
Sarasota, Florida, United States
- Research Site
Atlanta, Georgia, United States
- Research Site
New Orleans, Louisiana, United States
- Research Site
Bethesda, Maryland, United States
- Research Site
Omaha, Nebraska, United States
- Research Site
Rochester, New York, United States
- Research Site
Nashville, Tennessee, United States
- Research Site
Charlottesville, Virginia, United States
- Research Site
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Jun 2018
- Primary completion
- 31 Mar 2021
- Completion
- 31 Mar 2021
- Last update posted
- 15 Aug 2022
- Registered enrollment
- 30
- Registry id
- NCT03527147
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.